Naoki Niikura
@NaokiNiikuraProfessor Tokai University, Department of breast surgery, Clinical and Translational researcher, I love a family, triathlon ,travel, Yoga
Similar User
@shimoi_oncology
@bc_tube
@YukinoriOzaki
@konishita_sur
@Masato_Nyusen
@TUH_DMO
@ToshimiHBM
@cancer_ref
@kazuki_nozawa
@gantaisaku1105
@ShuYazaki
@JSMO_official
@MamMa_mimumemo
@jcaopl
@koki_fitness
1つの選択肢、natureにアクセプト、この意味は大きい
The results of SONIA are out on @Nature 1L use of palbo did not improve PFS over 2L use, but led to more AEs & costs. An evolving treatment landscape challenges its interpretation— yet it shows that sequencing trials are possible. Congrats to the authors! nature.com/articles/s4158…
T-DXd Demonstrates Efficacy in HER2+ Metastatic Breast Cancer With Stable or Active Brain Metastases @nlinmd @DanaFarber #bcsm #oncology onclive.com/view/t-dxd-dem…
TROPION-BREAST01 DaTO-DXd vs Chemo for HR+\HER2- PFS延長もOS延長を示すことができず。
Press release: despite improving PFS vs chemo, Dato-DXd did not meet the dual primary endpoint of OS for HR+/HER2- MBC in the TROPION-Breast01 trial. Full data at #SABCS24? astrazeneca.com/media-centre/p…
KN-522 update OS Chemo + Pembro prolong OS HR 0.66 5y OS 88.6%
Impressive!!
📌 Rates of pathologic complete response (pCR) after datopotamab deruxtecan (Dato) in the neoadjuvant setting: Results from the I-SPY 2.2 trial @MeghnaTrivedi3 #ESMO24 @OncoAlert #OncoAlertAF • Highest pCR rate observed in Immune+ (79%) followed by TNBC (62%) subtypes • > 50%…
#ESMO24 | DESTINYBreast-12: arrivano gli attesi risultati di T-DXd nel #carcinomamammario metastatico con o senza metastasi cerebrali. Il commento a caldo di @BianchiniGP 👇🏼 Non perdere l’intervista completa a breve su Oncoinfo! 🔜 @myESMO
DB-12の結果はNature medicineに同時発表されています。
🔥Hot off the Press! Trastuzumab deruxtecan in HER2-positive advanced #BreastCancer with or without #BrainMetastases practice changing results from a phase 3b/4 trial. 🔓nature.com/articles/s4159… #ESMO24 @NatureMedicine @nlinmd @Prof_Nadia_H @evaciruelos @volkmar_mueller…
HER3-Dxd HR+\HER2- ORR 53.5% mPFS 9.4 m HER2 0 40% patients
DB-12 T-DXd for with or without Brain metastasis. 12month mCNS-PFS 58.9% Active BM 60.1% Stable BM 57.8% No different mCNS-PFS active and stable BM
📌 Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and/or leptomeningeal metastases 🧠: an updated overall survival analysis using data from a multicenter retrospective study (ROSET-BM) | Breast Cancer link.springer.com/article/10.100……
Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and/or leptomeningeal metastases: an updated overall survival analysis using data from a multicenter retrospective study (ROSET-BM) was published from BC link.springer.com/article/10.100…
Continuing medical education (CME)の日本版を担当します。 1年前のESMO2023の内容になり,日本語訳もついています HR+Adj、ADCの1時間のディスカッション(日本語でOK)を行います。 医師、看護師、薬剤師などの医療関係者は参加可能です。定員は15名の先着順ですscientificseminars.gathered.com/invitation?ref…
《朗報》 2日の第二部会にてフリュザクラ(大腸がん)、タフィスゴ(FGFR2融合遺伝子陽性胆道がん)、アレセンサ(ALK融合遺伝子陽性肺がんの術後補助療法)の承認が了承され、キイトルーダの非小細胞肺がんにおける術前・術後補助療法の承認が報告された。 gantaisaku.net/yakuji_240802/
脳転移/髄膜がん腫症を伴うHER2+乳がんへのT-DXd、長期の有効性を評価(ROSET-BM)/日本乳癌学会 Carenet医療ニュース #carenet carenet.com/news/general/c…
CIPNの発症率は、対照群で70.6%であったのに対し、SMT群では30.0%、WBVトレーニング群では41.2%であり、対照群に比べて介入群で減少 タキサン系でも同じ結果になるか? 運動が化学療法による末梢神経障害の回避に有効か Carenet医療ニュース #carenet carenet.com/news/general/h…
Phase 1 trial of the HER2 topo1 ADC SHR-A1811 out in @JCO_ASCO Impressive activity among pts with HER2+ (ORR 76%, left) and HER2-low (ORR 60%, right) MBC, & in multiple other tumor types. ILD: 2.6%, 13 deaths due to AEs (4.2%), 4 treatment-related (1.3%). ascopubs.org/doi/10.1200/JC…
インパクトファクター503.1とか一生かかっても獲得できない数字、インフレが止まらないですね
The 2023 Impact Factor for CA: A Cancer Journal for Clinicians is 503.1. CA is proud to continue its commitment to publishing free-to-access, high-quality content aligned with the @AmericanCancer mission to end cancer as we know it, for everyone.
United States Trends
- 1. Spotify 2,84 Mn posts
- 2. Snape 5.021 posts
- 3. Pete 943 B posts
- 4. CEOs 30,2 B posts
- 5. $EMT 4.086 posts
- 6. Mbappe 173 B posts
- 7. $HAWK 7.409 posts
- 8. Hawk Tuah 26,1 B posts
- 9. #EarthMeta 1.668 posts
- 10. Sister Jean 1.077 posts
- 11. United Healthcare 97,1 B posts
- 12. Arsenal 428 B posts
- 13. Brian Thompson 170 B posts
- 14. Preemptive 39,4 B posts
- 15. UHC CEO 11 B posts
- 16. Alan Rickman N/A
- 17. Anthony Fauci 34,7 B posts
- 18. Citibike 12,6 B posts
- 19. Team USA 6.932 posts
- 20. Chipotle 9.143 posts
Who to follow
-
tatsunori_shimoi
@shimoi_oncology -
BC Tube 編集部|乳腺・乳がんに関する医療情報発信
@bc_tube -
Yukinori Ozaki
@YukinoriOzaki -
KONISHI Takaaki@外科
@konishita_sur -
高橋將人(北海道大学病院乳腺外科教授)
@Masato_Nyusen -
東北大学病院腫瘍内科
@TUH_DMO -
高野 利実 Toshimi Takano
@ToshimiHBM -
海外がん医療情報リファレンス
@cancer_ref -
Kazuki Nozawa, MD
@kazuki_nozawa -
日本がん対策新聞@かんぱち編集長
@gantaisaku1105 -
Shu Yazaki, MD, PhD
@ShuYazaki -
日本臨床腫瘍学会(JSMO)
@JSMO_official -
Mitsuo Terada, MD, PhD@乳腺科医
@MamMa_mimumemo -
一般社団法人日本癌学会
@jcaopl -
リオールジム / 女性向けメディカルジム
@koki_fitness
Something went wrong.
Something went wrong.